Metropolis Healthcare Limited has informed the Exchange regarding a press release dated August 07, 2025, titled "Metropolis Healthcare delivers strong Q1FY26 performance with 23% Revenue Growth to INR 386 Crore; PAT up 19% YoY".
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Metropolis Healthcare reported Q1FY26 (quarter ended June 30, 2025) consolidated revenue of INR 386 Crore, up 23% year-on-year, with EBITDA at INR 45 Crore and PAT rising 19% YoY. Patient and test volumes grew 11% and 12% respectively, while revenue per patient and revenue per test improved 11% and 10% driven by a richer test mix. The B2C and B2B businesses grew 19% and 29% YoY, with Specialty Diagnostics leading at 32% growth on the back of Oncology, Genomics, and NGS traction. The TruHealth wellness portfolio expanded 24%, and North India's revenue share rose to 17% from 8%, reflecting successful geographic diversification. Recent acquisitions have been fully integrated, and management highlighted reduced pricing pressure and a focus on clinical quality.
Strong, broad-based growth across volumes, realizations, and segments signals healthy operational momentum. Likely positive sentiment for the stock as it reflects consistent execution, premium test mix expansion, and scalable growth levers across geographies.